<bill session="109" type="h" number="5115" updated="2023-01-13T04:48:45Z">
  <state datetime="2006-04-06">REFERRED</state>
  <status>
    <introduced datetime="2006-04-06"/>
  </status>
  <introduced datetime="2006-04-06"/>
  <titles>
    <title type="display">U.S. Healthcare Technologies Competitiveness Act of 2006</title>
    <title type="official" as="introduced">To amend the Internal Revenue Code of 1986 to modernize the tax treatment of biomedical research corporations.</title>
    <title type="short" as="introduced">U.S. Healthcare Technologies Competitiveness Act of 2006</title>
  </titles>
  <sponsor bioguide_id="H001033"/>
  <cosponsors>
    <cosponsor bioguide_id="E000187" joined="2006-04-06"/>
    <cosponsor bioguide_id="R000033" joined="2006-04-27"/>
    <cosponsor bioguide_id="W000273" joined="2006-04-06"/>
  </cosponsors>
  <actions>
    <action datetime="2006-04-06">
      <text>Introduced in House</text>
    </action>
    <action datetime="2006-04-06" state="REFERRED">
      <text>Referred to the House Committee on Ways and Means.</text>
    </action>
  </actions>
  <committees>
    <committee code="HSWM" name="House Ways and Means" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills/>
  <subjects>
    <term name="Taxation"/>
    <term name="Accounting"/>
    <term name="Biomedical engineering"/>
    <term name="Biotechnology"/>
    <term name="Capital gains tax"/>
    <term name="Charities"/>
    <term name="Clinical trials"/>
    <term name="Commerce"/>
    <term name="Corporate finance"/>
    <term name="Corporation taxes"/>
    <term name="Depreciation and amortization"/>
    <term name="Drug industry"/>
    <term name="Drugs"/>
    <term name="Finance and Financial Sector"/>
    <term name="Foundations"/>
    <term name="Government Operations and Politics"/>
    <term name="Government paperwork"/>
    <term name="Health"/>
    <term name="Hospitals"/>
    <term name="Income tax"/>
    <term name="Influenza"/>
    <term name="Interest"/>
    <term name="Investments"/>
    <term name="Losses"/>
    <term name="Medical innovations"/>
    <term name="Medical research"/>
    <term name="Medical supplies"/>
    <term name="Minimum tax"/>
    <term name="Orphan drugs"/>
    <term name="Pharmaceutical research"/>
    <term name="Real estate development"/>
    <term name="Research and development tax credit"/>
    <term name="Research centers"/>
    <term name="Science, Technology, Communications"/>
    <term name="Scientific instruments and apparatus"/>
    <term name="Small business"/>
    <term name="Social Welfare"/>
    <term name="Stocks"/>
    <term name="Tax credits"/>
    <term name="Tax deductions"/>
    <term name="Tax exclusion"/>
    <term name="Tax incentives"/>
    <term name="Tax-exempt securities"/>
    <term name="Technology transfer"/>
    <term name="Vaccines"/>
    <term name="Valuation"/>
  </subjects>
  <amendments/>
  <summary date="2006-05-13T14:15:30Z" status="Introduced in House">U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such corporations; (2) permitting a complete offset against the alternative minimum tax for the net operating losses of biomedical research corporations; (3) making permanent and increasing the rates for the tax credit for increasing research activities; (4) allowing tax credits for countermeasures equity investments and research expenses, qualified medical innovation expenses, equity investments in incubational companies, and investment in qualified biotechnology zone bonds; (5) accelerating eligibility for the tax credit for orphan drug expenses; (6) allowing expensing of biotechnology science park property and medical research equipment; (7) allowing deferral of the tax on gain from the sale of stock in a biomedical research corporation; (8) increasing the tax deductibility of capital losses on the sale of stock in biomedical research corporations; and (9) modifying passive loss deduction rules and S corporation shareholder requirements for biomedical research corporations.</summary>
</bill>
